Replies to post #223656 on Biotech Values

[DewDiligence]

PRTO PATENCY-2 results:

https://finance.yahoo.com/news/proteon-therapeutics-announces-top-line-120000017.html

Proteon Therapeutics…today announced results from PATENCY-2, its Phase 3 clinical trial of investigational vonapanitase in patients with chronic kidney disease (CKD) undergoing creation of a radiocephalic fistula for hemodialysis. This study did not meet its co-primary endpoints of fistula use for hemodialysis (p=0.328) and secondary patency (p=0.932).

I.e., placebo-like efficacy.

[poorgradstudent]

PRTO:

Sorry, I missed this a long time ago.

Whereas vonapanitase did not meet its primary end point, there were several clinically meaningful indicators that vonapanitase may be an effective therapy in fistula creation.
Importantly, vonapanitase was associated with increases in secondary patency and use of the fistula for hemodialysis.

I would have said the same as before. I think the scientific basis was very weak on this one and it seems the story is now over.